Altern Ther Health Med. 2024 Oct;30(10):238-243.
To investigate the mortality rate of patients with Omicron infection before and after the implementation of the new crown standard, and to evaluate the impact of new treatment protocols on the mortality rate of patients with Omicron infection.
Clinical data of 1419 Omicron-infected patients treated in our hospital from April 10, 2022 to June 3, 2022 were collected(Patients diagnosed with Omicron infection who met the diagnostic criteria in the "Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 9)"15 and whose nasal/pharyngeal swab samples were typed as Omicron variants by laboratory viral genotyping). They were divided into the observation group (April 25 2022 - June 3 2022) and the control group (April 10 2022 - April 24 2022) before and after the implementation criteria. Clinical data of 1419 patients were collected and compared between the two groups on whether to use anticoagulant drugs, whether to use antiplatelet drugs, gender, whether to use new drugs of thymosin/thymus method, age, whether to use herbal medicine, whether to use Fuzheng prescription, blood routine, liver function, kidney function indicators, mortality of patients.
A total of 1419 patients were initially selected; 501 patients with incomplete information were excluded, and finally, 918 patients were included. According to the time period before and after the application criteria, they were divided into an observation group (586 cases) and a control group (332 cases). There were no statistically significant differences in gender, age, antiplatelet drug use, and herbal medicine use between the two groups (P < .05). However, there were significant differences in the use of anticoagulant drugs, thymidine/thymidine drugs, and Fu Zhengfang between the two groups. It was statistically significant that the mortality rate in the observation group (2.39)% was significantly lower than that in the control group (5.12)%. P < .05 White blood cell count, red blood cell ratio, lymphocyte count, hemoglobin, neutrophil count, and neutrophil ratio were not significantly different between the two groups (P < .05) .In comparison to the control group (4.92±8.00)10^9/L, the platelet count in the observation group (4.77±3.41)109/L was considerably lower. The difference was statistically significant (P < .05). The comparison of total bilirubin, total protein values and alkaline phosphatase values between the two groups was not significant (P < .05). In the observation group, albumin (38.71±6.39) g/L, glutamate transaminase (23.93±26.03) U/L, glutathione transaminase (26.12±25.53) U/L, gamma-glutamyltransferase (34.28±52.3) U/L, globulin values (28.13±5.55) g/L were significantly lower than those of the control group (36.66±7.08) g/L, (30.36±65.77) U/L, (33.29±49.72) U/L, (43.76±80.23) U/L, (29.85±5.67) g/L, the difference was statistically significant (P < .05). Between the two groups, there were no significant differences in the values of uric acid or creatinine (P > .05). Levels and uric acid readings did not differ significantly, P > .05. The difference between the urea values of the observation group (7.44±6.34 mmol/L) and the control group (8.75±7.51 mmol/L) was statistically significant (P < .05).
After the implementation of the treatment protocol for COVID-19 (Trial Version 9), the number of death cases among patients with Omicron variant infection has significantly decreased. The treatment protocol is safe and feasible and can be widely applied in clinical settings..And it will further promote the development and administration of vaccines to prevent and control the spread of the novel coronavirus, reducing the occurrence of patients and death cases.
探讨奥密克戎感染患者实施新冠新标准前后的病死率，并评估新的治疗方案对奥密克戎感染患者病死率的影响。
收集我院 2022 年 4 月 10 日至 6 月 3 日收治的 1419 例奥密克戎感染患者的临床资料（符合《新型冠状病毒肺炎诊疗方案（试行第九版）》15 中诊断标准，且实验室病毒基因分型提示为奥密克戎变异株的鼻/咽拭子样本）。将患者分为观察组（2022 年 4 月 25 日-6 月 3 日）和对照组（2022 年 4 月 10 日-4 月 24 日）。收集两组患者的临床资料，比较两组患者是否使用抗凝药物、抗血小板药物、性别、是否使用胸腺法新/胸腺肽类新药、年龄、是否使用中草药、是否使用扶正方剂、血常规、肝功能、肾功能指标、患者病死率。
共入选 1419 例患者，排除信息不完整患者 501 例，最终纳入 918 例。根据应用标准前后的时间段分为观察组（586 例）和对照组（332 例）。两组患者性别、年龄、抗血小板药物使用、中草药使用比较，差异无统计学意义（P ＜ 0.05）；两组患者抗凝药物使用、胸腺法新/胸腺肽类新药、扶正方剂使用比较，差异有统计学意义（P ＜ 0.05）。观察组病死率（2.39）%显著低于对照组（5.12）%，差异有统计学意义（P ＜ 0.05）。两组患者白细胞计数、红细胞比容、淋巴细胞计数、血红蛋白、中性粒细胞计数、中性粒细胞比比较，差异无统计学意义（P ＜ 0.05）。观察组血小板计数（4.77±3.41）×10^9/L 显著低于对照组（4.92±8.00）×10^9/L，差异有统计学意义（P ＜ 0.05）。两组患者总胆红素、总蛋白、碱性磷酸酶值比较，差异无统计学意义（P ＜ 0.05）。观察组患者白蛋白（38.71±6.39）g/L、谷草转氨酶（23.93±26.03）U/L、谷胱甘肽转移酶（26.12±25.53）U/L、γ-谷氨酰转移酶（34.28±52.3）U/L、球蛋白值（28.13±5.55）g/L 显著低于对照组（36.66±7.08）g/L、（30.36±65.77）U/L、（33.29±49.72）U/L、（43.76±80.23）U/L、（29.85±5.67）g/L，差异有统计学意义（P ＜ 0.05）。两组患者尿酸、肌酐值比较，差异无统计学意义（P ＞ 0.05）。两组尿素值比较，观察组（7.44±6.34）mmol/L 与对照组（8.75±7.51）mmol/L 差异有统计学意义（P ＜ 0.05）。
实施《新型冠状病毒肺炎诊疗方案（试行第九版）》后，奥密克戎变异株感染患者的死亡例数明显减少。该治疗方案安全可行，可在临床广泛应用，并将进一步推动新冠病毒疫苗的研发和管理，以预防和控制病毒的传播，减少患者和死亡病例的发生。
